targetedoncology

Sevabertinib Yields Antitumor Activity in Non–Small Cell Lung Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Orphan Drug Designation Granted to Exosome-Based Treatment for GBM | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Omacetaxine and Venetoclax Show Benefits in MDS, No Improvement in AML | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Fast Tracks Anti-HER2 Biparatopic ADC for Platinum-Resistant Ovarian Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Fast Track Status to MT-125 in Glioblastoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Novel ADC Pamlectabart Tismanitin Earns FDA Fast Track for Myeloma Treatment | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Oncologists Choose Top Goals and Therapies for Treating MDS | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways